Dicot Pharma Dicot Pharma
På svenska

We develop the next generation potency drug.

To enhance quality of life for men and couples worldwide.

Over 500 million men worldwide suffer from erectile dysfunction and premature ejaculation. Dicot Pharma is developing an entirely new potency drug aimed at creating a treatment with longer duration, fewer side effects, and effectiveness for a significantly broader group compared to existing market alternatives.

Press Releases

Dicot Pharma’s World in Numbers

Approx.
billion SEK/year
The global sales of erectile dysfunction treatments.
Approx.
percent
The proportion of men with erectile dysfunction who discontinue treatment with current medications.
At least
days
LIB-01's duration from exploratory measurements in the Phase 1 study.
percent
Subscription rate in the August 2024 rights issue.

Read Dicot Pharma's Annual Report 2024!

In the Annual Report you'll find an exclusive interview with renowned sexual medicine expert Professor François Giuliano, insights into the clinical studies, a look at how the market could expand dramatically with the right triggers – and much more.

Financial calendar and events

Breaking Barriers in Sexual Health: Dicot Pharma’s LIB-01 and the Future of ED Treatment

Recently, CEO Elin Trampe appeared on the BioBiz Buzz podcast in a conversation with biotech industry veteran Mike Ward — a renowned analyst and thought leader known for interviewing top executives, investors, and innovators across the life science sector.

In this episode, they discuss the clinical development of LIB-01, opportunities for strategic partnerships, and the ongoing work to reduce the stigma around erection problems.